The COVIDome online portal can rapidly accelerate coronavirus research worldwide

To further accelerate COVID-19 research on a global scale, investigators from the University of Colorado Anschutz Medical Campus have created a multidimensional dataset, known as the COVIDome dataset, derived from hospitalized COVID-19 patients versus negative controls. The team has now launched a public online portal called the COVIDome Explorer to share that data in real time.

Today, a new paper published in the journal Cell Reports detailing how the datasets were generated while explaining how to use the COVIDome Explorer for rapid hypotheses testing, hypothesis generation and real-time discoveries by experts and non-experts.

"Our mission for the COVIDome Explorer is to enable the development of better prevention, diagnostic and therapeutic tools for the clinical management of COVID-19," said Joaquin Espinosa, PhD, professor at the University of Colorado School of Medicine and executive director at the Linda Crnic Institute for Down Syndrome on the CU Anschutz Medical Campus. "Although great progress has been made in all these areas, the speed of research for COVID-19 has been hampered by the lack of widely accessible, public datasets that can be analyzed and reanalyzed in real time by anyone."

He adds, "We expect that this online portal will rapidly accelerate COVID-19 data sharing, hypothesis testing and discoveries worldwide."

To create the COVIDome Explorer, experts in different areas of biomedical research across the CU Anschutz Medical Campus created multidimensional datasets in their labs. Those were collected and combined to be shared through the online portal. The datasets include demographics and clinical data, along with matched analysis of the whole blood transcriptome, analysis of the plasma and red blood cell metabolomes, deep immune phenotyping by mass cytometry and seroconversion assays.

The COVIDome datasets and corresponding Explorer were modeled after similar ongoing efforts in the Linda Crnic Institute for Down Syndrome, where members of the COVIDome team previously developed the Human Trisome Project and its TrisomExplorer data portal. Leveraging the leading-edge tools and technologies of the TrisomExplorer, the team was able to create the COVIDome Explorer in a matter of weeks and make it available to the public to help advance COVID-19 research.

"The global health crisis imposed by the COVID-19 pandemic further emphasizes the need for rapid collaboration, open access to manuscripts under review and data sharing," said Thomas Flaig, MD, vice chancellor of research at the CU Anschutz Medical Campus. "Now more than ever, with the rise of the COVID-19 Delta variant and breakthrough infection rates rising, it’s critical to have easy and timely access to COVID data to combat the pandemic and advance the best scientific data available."

The paper, which users are encouraged to read, details how to use the online dashboards and links to data files that guide users, such as catalogs of proteins, metabolites, cytokines and immune cells present in each dataset.

For example, to facilitate quick and broad access to the COVIDome dataset, each dataset (after data curation and quality control) is linked at the sample level with a unique identifier, enabling cross-referencing among platforms. Additionally, the COVIDome Explorer hosts six dashboards: Cohort, Transcriptome, Proteome, Cytokines, Metabolome, and Immune Maps. And each dashboard runs within its own isolated and protected environment.

The COVIDome Project is a partnership between the CU School of Medicine and the Office of the Vice Chancellor for Research, co-led by Joaquin Espinosa, PhD, and Thomas Flaig, MD.

Sullivan KD, Galbraith MD, Kinning KT, Bartsch KW, Levinsky NC, Araya P, Smith KP, Granrath RE, Shaw JR, Baxter RM, Jordan KR, Russell SA, Dzieciatkowska ME, Reisz JA, Gamboni F, Cendali FI, Ghosh T, Monte AA, Bennett TD, Miller MG, Hsieh EW, D'Alessandro A, Hansen KC, Espinosa JM.
The COVIDome Explorer researcher portal. Cell Rep. 2021 Jul 28:109527. doi: 10.1016/j.celrep.2021.109527

Most Popular Now

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...

GSK and Vir Biotechnology announce United States g…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase so...

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer and BioNTech receive expanded U.S. FDA emer…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...